H

    HCW Biologics Inc (HCWB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.59
    +0.16 (+4.66%)

    Market Cap: $6.59M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    39%(7/18)
    Avg Surprise
    -59.49%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.08
    Range$-1.08 - $-1.08
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-1.26-16.7%
    60d ago$-1.26-16.7%
    30d ago$-1.26-16.7%
    7d ago$-1.08+0.0%
    Current$-1.08
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.62
    Range$0.62 - $0.62
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.62---
    Sep 26EST
    		-$-1.08---
    Jun 26
    Reported Aug 7
    		$-10.10$-1.98-410.10%Miss-48.7%
    Mar 26
    Reported May 14
    		$2.22$-2.64+184.09%Beat+4540.0%
    Dec 25
    Reported Mar 31
    		$-6.12$-5.04-21.43%Miss+68.1%
    Sep 25
    Reported Nov 14
    		$-12.12$9.48-227.85%Miss+49.5%
    Jun 25
    Reported Aug 18
    		$-6.79$10.80-162.87%Miss+92.9%
    Mar 25
    Reported May 15
    		$-0.05$0.00N/ABeat+99.9%
    Dec 24
    Reported Mar 28
    		$-19.20$21.60-188.89%Miss-6300.0%
    Sep 24
    Reported Nov 14
    		$-24.00$-31.20+23.08%Beat+28.6%
    Jun 24
    Reported Aug 14
    		$-96.00$-43.20-122.22%Miss-233.3%
    Mar 24
    Reported May 15
    		$-72.00$-36.00-100.00%Miss-51328.6%
    Dec 23
    Reported Mar 26
    		$-0.30$-0.14-106.90%Miss+99.2%
    Sep 23
    Reported Nov 14
    		$-33.60$-31.20-7.69%Miss-27.3%
    Jun 23
    Reported Aug 11
    		$-28.80$-37.20+22.58%Beat-20.0%
    Mar 23
    Reported May 9
    		$-0.14$-0.14+0.00%Beat+99.0%
    Dec 22
    Reported Mar 28
    		$-36.00$-34.80-3.45%Miss-21076.5%
    Sep 22
    Reported Nov 7
    		$-26.40$-31.20+15.38%Beat-32900.0%
    Jun 22
    Reported Aug 12
    		$-24.00$-30.00+20.00%Beat-11900.0%
    Mar 22
    Reported May 13
    		$-14.40N/A+57.14%Beat-2091.8%
    Dec 21
    Reported Mar 29
    		$-0.17$-0.12-41.67%Miss+75.2%
    Sep 21
    Reported Nov 12
    		$-0.08N/AN/ABeat+87.3%
    Jun 21
    Reported Aug 13
    		$-0.20$0.00N/AMiss+69.1%
    Mar 21
    Reported Jun 30
    		$-0.66$0.00N/AMiss-16.7%
    Dec 20
    Reported Mar 31
    		$-0.69$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-0.63$0.00N/AMiss-
    Mar 20
    Reported Jun 30
    		$-0.65$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-0.56$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.14EV/EBITDA-3.63x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-83.10%Operating Margin-2336.00%
    ROE-151.40%ROIC-72.12%
    Financial Health
    Debt/Equity0.88xInterest Coverage1.88x
    Current Ratio0.06xQuick Ratio0.06x
    Trading Statistics
    Beta2.36Avg Volume168.49K
    52-Week High$36.6552-Week Low$1.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.65
    SMA 20$2.90
    SMA 50$3.75
    SMA 200$6.02
    EMA 10$2.95
    EMA 20$2.99
    EMA 50$3.77
    EMA 200$9.97

    MACD

    Line: -0.20Signal: -0.40Hist: 0.20

    ADX

    ADX: 19.3+DI: 21.2-DI: 11.2

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down76.0
    PSAR$3.96

    Bollinger Bands

    Upper Band$3.94
    Lower Band$1.86
    %B Position7164%(Upper)
    Band Width0.83

    RSI (14-Day)

    Neutral
    57.8

    Momentum Oscillators

    Stoch %K89.5
    Stoch %D69.0
    Williams %R-0.6
    ROC (10d)42.5%
    Momentum1.07
    CCI (20d)85.6
    MFI (14d)42.2

    Volatility Measures

    ATR (14d)$0.65(18.1%)
    StdDev (20d)0.52
    Hist Vol127.6%(High)

    Volume Flow

    VWAP$3.47
    OBV1.2B
    AD Line69.5B
    CMF (20d)-0.156

    Volume Metrics

    Avg Vol (20d)162.5K
    Vol Ratio0.4x(Low)
    VWMA (20d)$2.56

    Pivot Points

    R3$4.00
    R2$3.72
    R1$3.57
    Pivot Point$3.29
    S1$3.14
    S2$2.86
    S3$2.71

    Advanced Oscillators

    TSI-14.08
    Ultimate Osc66.1
    KST-229.51

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$135,568$6.54M$27,011$15,606$6,550$5,065$394,803$426,423$618,854$1.13M$1.32M$853,102
    Cost of Revenue$229,455$11,071$21,609$12,485$5,240$4,052$315,843$341,138$438,443$511,965$1.07M$678,325
    Gross Profit$-93,887$6.53M$5,402$3,121$1,310$1,013$78,960$85,285$180,411$614,747$252,645$174,777
    Operating Expenses$3.07M$3.30M$4.45M$3.30M$3.47M$1.97M$3.22M$3.77M$15.32M$8.11M$11.02M$5.25M
    R&D$1.20M$1.26M$1.33M$1.40M$1.23M$1.48M$1.05M$1.19M$2.03M$2.12M$2.14M$1.67M
    SG&A$1.87M$1.83M$1.49M$1.88M$2.10M$2.23M$2.02M$1.63M$1.59M$1.57M$564,428$1.51M
    Operating Income$-3,166,289$3.24M$-4,440,505$-3,292,126$-3,464,077$-1,965,802$-3,142,307$-3,684,540$-15,136,010$-7,493,663$-10,768,189$-5,077,880
    Interest Income$0$0$0$0$1.75M$0$0$0$0$0$0$0
    Interest Expense$-382,842$109,274$-5,227,601$127,070$228,714$255,822$265,560$229,058$159,666$0$-1,424$95,514
    Income Before Tax$-5,219,231$3.80M$801,060$-4,372,190$-1,927,730$-2,196,875$-3,373,274$-3,902,288$-15,280,191$-7,468,061$-10,680,530$-4,938,641
    Income Tax Expense$0$330,186$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,219,231$3.47M$719,232$-4,554,336$-1,927,730$-2,196,875$-3,373,274$-3,902,288$-15,280,191$-7,468,061$-10,680,530$-4,938,641
    EBITDA$-5,474,978$4.05M$-3,996,179$-4,071,215$-3,155,788$-1,522,043$-2,425,207$-3,544,781$-14,990,593$-7,224,560$-10,407,404$-4,565,673
    EBIT$-5,602,073$3.91M$-4,153,119$-4,245,120$-3,447,704$-1,941,053$-3,107,714$-3,673,230$-15,120,525$-7,468,061$-10,681,954$-4,843,127
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HCWB

    News

    HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion

    HCW Biologics announced that human studies of its TGF-β trap and IL-15 fusion demonstrated the expansion of progenitor CD8+ T cells and Natural Killer cells in cancer patients. The company's fusion also showed activity against HIV-1 and bronchopulmonary dysplasia in animal models, with findings published in scientific journals. HCW Biologics is incorporating this moiety into second-generation cancer therapies, with clinical studies planned to begin in 2027.

    Investing.com•8/25/26•
    Bullish

    HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion

    HCW Biologics announced that human studies of its TGF-β trap and IL-15 fusion demonstrated expansion of progenitor CD8+ T cells and Natural Killer cells in cancer patients. The biopharmaceutical company's fusions also showed activity against HIV-1 and bronchopulmonary dysplasia in animal models, with findings published in scientific journals. HCW Biologics plans to initiate clinical studies in 2027 for its lead product candidates, HCW11-018b and HCW11-040, which incorporate this fusion technology.

    Investing.com India•8/25/26•
    Bullish

    HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

    HCW Biologics announced that its TGF-β trap and IL-15 fusion is a novel moiety with potential to enhance immunotherapeutic activity against diseased cells and viral infections. Human studies have shown it promotes the expansion of progenitor CD8+ T cells and NK cells, providing clinical benefit in cancer patients and activity against HIV-1 and bronchopulmonary dysplasia in animal models. The company has incorporated this discovery into its second-generation T Cell Engager and Immune Checkpoint Inhibitor programs, with lead candidates expected to begin clinical studies in 2027.

    GlobeNewswire•8/25/26•
    Bullish

    Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells

    HCW Biologics announced that human studies of its TGF-β trap and IL-15 fusion showed expansion of progenitor CD8+ T cells and natural killer cells, good tolerability, and clinical benefit in cancer patients. This novel moiety has been incorporated into their second-generation immunotherapeutics, HCW11-018b (a TCE candidate) and HCW11-040 (an ICI candidate), both at the IND-enabling stage with clinical studies planned for 2027. Preclinical models also demonstrated activity against HIV-1 and bronchopulmonary dysplasia, and HCW11-040 showed superior immune-cell activation compared to pembrolizumab in preclinical studies.

    Stock Titan•8/25/26•
    Neutral

    HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares

    HCW Biologics Inc. has filed a Form S-1 to register the resale of up to 1.24 million shares of common stock, including shares from a July 2026 PIPE financing and shares issuable upon exercise of pre-funded and common warrants. The company will not receive proceeds from the resale of registered shares, but may receive up to $1.6 million if common warrants are approved and exercised for cash. The filing highlights risks such as dilution, potential stock price declines, and Nasdaq listing compliance issues, while also noting the company's status as an emerging growth and smaller reporting company.

    Stock Titan•8/20/26•
    Neutral

    Frequently Asked Questions About HCWB

    Does HCWB pay dividends?
    HCW Biologics Inc (HCWB) does not currently pay a regular dividend.
    What is HCWB's market cap?
    HCW Biologics Inc (HCWB) has a market capitalization of $6.59M with a current stock price of $3.59.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In